Nasdaq

Merit Medical Systems Reports Promising Six-Month and Twelve-Month Results for WRAPSODY CIE in WAVE Trial

Merit Medical Systems, Inc. announced promising results from the six- and twelve-month follow-ups of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial, which evaluates the WRAPSODY Chronic ...
Nasdaq

Merit Medical Systems Announces Approval of WRAPSODY Cell-Impermeable Endoprosthesis in Canada for Hemodialysis Patients

Merit Medical Systems, Inc. has received regulatory approval from Health Canada for its WRAPSODY Cell-Impermeable Endoprosthesis (CIE), a device designed to enhance functional vascular access for ...
Seeking Alpha

First Patient Enrolled in Merit Medical’s WRAPSODY (WRAP) North America Registry

SOUTH JORDAN, Utah, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (MMSI), a global leader of healthcare technology, announced today the successful enrollment of the first patient in ...
Seeking Alpha

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm ...
Investing

Merit’s WRAPSODY device shows superior results in dialysis study

SOUTH JORDAN, Utah - Merit Medical Systems, Inc. (NASDAQ:MMSI) announced that its WRAPSODY Cell-Impermeable Endoprosthesis (CIE) demonstrated significantly better outcomes than standard percutaneous ...
Business Insider

Merit Medical Receives FDA Breakthrough Device Designation for WRAPSODY™ Endovascular Stent Graft System

SOUTH JORDAN, Utah, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, ...